BioCentury
ARTICLE | Company News

ICER panel says long-term value for Aimovig for migraines is intermediate

June 15, 2018 7:59 PM UTC

ICER's California Technology Assessment Forum (CTAF) voted that the long-term value of calcitonin gene-related peptide (CGRP) inhibitor Aimovig erenumab for patients with chronic migraine who had previously failed other preventative migraine treatments was intermediate, while the panel was mixed on whether long-term value for patients with episodic migraine who previously failed other preventative therapies was low or intermediate.

For patients with chronic migraine, or 15 or more migraine days per month, 12 members voted that the long-term value for money for Aimovig from Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN) was intermediate, while one member voted that the value was high. For patients with 14 or fewer migraine days per month, six panel members voted that the value was low, while seven members voted that the long-term value for money was high...